NCT06922591 · Tango Therapeutics, Inc.
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
What this study is about
TNG462-C102 is a Phase 1/2, where both patients and doctors know the treatment given, conducted at multiple hospitals study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of taken by mouth TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a gradually increasing doses phase and a dose expansion phase.
View original scientific description
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. The study comprises a dose escalation phase and a dose expansion phase.
Interventions
DRUG
TNG462
MTA cooperative PRMT5 inhibitor
DRUG
RMC-9805
RAS(ON) G12D selective covalent inhibitor
DRUG
RMC-6236
RAS(ON) multi-selective inhibitor
DRUG
mFOLFIRINOX
Chemotherapy
DRUG
gemcitabine/nab-paclitaxel
Chemotherapy
Primary outcome measures
Phase 1: Maximum Tolerated Dose
Time frame: 21 days
To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805
Phase 1: Maximum Tolerated Dose
Time frame: 28 days
To determine the MTD and RD(s) of TNG462 in combination with mFOLFIRINOX or gemcitabine/nab-paclitaxel
Phase 2: Combination Anti-neoplastic Activity
Time frame: 12 weeks
To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel using RECIST 1.1
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Is ≥18 years of age at the time of signature of the main study ICF. 2. Has an ECOG PS of 0 or 1. 3. Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene 4. Has a tumor with a RAS mutation 5. Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC 6. Has received prior standard therapy 7. Must not have received prior RAS-targeted therapy 8. Has evidence of measurable disease based on RECIST v1.1. 9. Adequate organ function 10. Must be able to swallow tablets. 11. Negative pregnancy test at screening 12. Written informed consent must be obtained according to local guidelines
Exclusion criteria
- Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor 2. Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805 3. Known allergy, hypersensitivity or intolerance to TNG462, RMC-6236, RMC-9805 or their excipients 4. Has uncontrolled intercurrent illness that will limit compli
Where
- Scottsdale, Arizona
- Denver, Colorado
- Washington D.C., District of Columbia
- Jacksonville, Florida
- Chicago, Illinois
- Indianapolis, Indiana
- Iowa City, Iowa
- Boston, Massachusetts
- Rochester, Minnesota
- Omaha, Nebraska
- New York, New York
- Chapel Hill, North Carolina
And 4 more locations — see the full list below.
Collaborators
Revolution Medicines, Inc.
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced May 14, 2026 · Source of record for eligibility and locations